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Efficacy of Three Antibiotic Loaded Biodegradable Polymer Coatings for Bone Screws. 
Major Professor: Warren O. Haggard, Ph.D. 
Biodegradable polymers have a potential for use in medical applications due to 
their tailorable mechanical properties and their biocompatibility.  Polymers have been 
used in applications ranging from sutures to dialysis filters and even for intraocular 
lenses.  The purpose of this research was to evaluate the potential use of the following 
biodegradable polymers: chitosan, poly l-lactic acid, and polyurethane, for potential use 
as a local antibiotic carrier through their use as coatings for orthopaedic fixation screws.  
Testing of the coatings included mechanical testing of the adhesion strength as well as 
biological testing using zone of inhibition, activity, and elution testing.  The results of 
this study demonstrated that polyurethane maintained on average the most amount of 
coating after insertion (98.2%) while all coatings produced a similar zone of inhibition.  
The elution from the chitosan coating at the 1 hour time point was the only elution that 





This thesis is presented with the understanding that the journal article submission 
is presented as the main body of work.  It is in that knowledge that the article titled, 
“Efficacy of Three Biodegradable Polymer Coatings Loaded with Tobramycin for Bone 
Screws,” has been submitted to the Journal of Orthopaedic Trauma.  Therefore the article 
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Chapter 1 INTRODUCTION 
1.1 Problem Statement 
 The ever-rising cost of health care and increasing rate of infection combined with 
increasing expectations from patients is driving healthcare providers and physicians to 
reduce patient infections as well as the hospital stays and the procedures associated with 
them.  The Center for Disease Control reported in 2009 that there were greater than 
500,000 surgical site infections per year1.  This represents a large strain on the financial 
well-being of the health care system and a large patient risk.  It has also been reported 
that the average cost of the treatment and subsequent surgeries for the revision to an 
arthrodesis (fusion of the joint) due to infection and or other contributing factors is 
$100,0002,3.  With the risk of infection to the patient and increasing costs is there a way 
for orthopaedic surgeons to incorporate a localized antibiotic into fracture fixation 
without adding any time or difficulty to surgery?  The use of a screw with local drug 
delivery capabilities has been long-discussed as a potential mechanism to mitigate the 
detrimental effects of bacteria in the fracture fixation of open fractures and wounds with 
high infection risk4.  One method of local delivery of antibiotics is through a screw with a 
degradable coating.  The question of the type of coating best suited for the application 
still remains unanswered. 
1.2  Hypothesis  
 The purpose of the study is to compare the effectiveness for local delivery of three 
different types of coatings for orthopaedic trauma implants.  The biomaterials to be tested 
are polylactic acid, chitosan, and polyurethane all loaded with a common antibiotic, 
tobramycin.  The hypothesis of this study is that these degradable biomaterial coatings 
will be effective carriers and local delivery systems for antibiotics under biological, 
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physical, and mechanical tests.  Effectiveness will be defined as retention of 80% of 
coating during insertion, active eluted antibiotics, and antibiotic elution profile for 
infection prevention.   
1.3 Literature Review 
1.3.1 Introduction 
 In light of the aforementioned clinical predicament of the increasing incidence of 
surgical site infections and the reported increase of 0.2% per year in orthopaedics3, three 
biomaterial coatings were selected to be researched and evaluated.  The primary criterion 
for the coatings was that they had to be degradable within the body4.  Additionally, the 
selection process encompassed one biomaterial that is currently used commercially for 
local antibiotic delivery5, one biomaterial that is being evaluated for clinical use as a local 
antibiotic carier6, and one novel biomaterial.  Therefore, polylactic acid, chitosan, and 
polyurethane were selected, respectively.   
1.3.2 Chitosan 
 Chitosan is a linear polysaccharide composed of N-acetyl glucosamine and D-
glucosamine, as shown by the molecular diagram in Figure 16-8. Chitosan is a naturally 
occurring polymer produced by the deacetylation of chitin, which is found in the 
exoskeleton of crustaceans.    The degree to which the chitin is deacetylated is known as 
the degree of deacetylation or DDA.  The DDA can be altered to tailor the degradation 
profile as well as the mechanical properties of the product produced from the chitosan6.  
Chitosan has been used in many applications, including coatings for medical implants, 
drug delivery, and bandages.  Its biocompatibility and biodegradable properties makes it 
an attractive selection for medical applications. 
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Figure 1. Molecular structure of Chitosan9 
 
 The degradation of chitosan in vivo is carried out by enzymatic degradation.   
Lysozymes in the body hydrolyze the glucosamine linkages, yielding saccharides and 
glucosamines.  These byproducts are found in the extracellular matrix of chitosan and 
therefore provide minimal biologic response following degradation10.     
 Researchers in the past have used chitosan in various forms for medical 
applications.  Green et al. used chitosan for a coating of a bone screw to be used in 
contaminated fractures6.  Norowski et al. used chitosan as a coating on titanium implant 
to elute antimicrobials.  Sivakumar et al. incorporated gentamicin into a chitosan and 
hydroxyapatite composite microsphere to characterize the release kinetics.  He showed 
that 80% of the antibiotic had been released at the 84 hour time point7.  Chitosan has also 
been explored as a replacement for polymethylmethacrylate beads for deep infections8.   
1.3.3 PLA  
 The use of poly lactic acid (PLA) has been well-defined in the past studies as a 
local delivery but less as a coating on a fracture fixation device11-13.  The polymer has 
been formed into plates and screws for small bone fixation, such as hand and foot 
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applications11.  Additionally, PLA has been utilized for sutures and patches for soft tissue 
injuries12,13.     
 Poly lactic acid is a polymer that is produced from bacterial synthesis of 
carbohydrates, such as corn and potatoes13.  PLA is unique in that the molecular weight 
and thus the degradation rate can be altered by altering the ratio of its two isomers (L, 
D)12,13.  The addition of the d-isomer reduces the glass transition temperature as well as 
the molecular weight of the polymer.  The ability of PLA to be tailored has made it an 
attractive choice for medical devices such as tissue patches, sutures and bone screws and 
plates13.  A figure showing a typical configuration of PLA is found in Figure 2. 
 
 
Figure 2. Representative molecular structure of Polylactic Acid14 
 
The typical degradation of the PLA in vivo is through the process of hydrolysis.  
The degradation products produced are lactic acid molecules that are naturally occurring 
in the body and can be broken down by the tricarboxylic acid cycle15.  Since the body is 
accustomed to processing PLA’s byproducts, PLA is non-toxic unless the buildup of 
lactic acid that occurs.  This buildup has been shown clinically to result in inflammation 
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following the intraosseous implantation of PLA16.  Additionally, a mild inflammatory 
response was reported by Paivarinta et al.17 and could lead to bone loss.   
1.3.4 Polyurethane 
 Polyurethane was selected as a potential biomaterial coating because of its prior 
applications in its non-degradable form, including hemodializers, catheters and wound 
dressings18,19.  Polyurethane has been used extensively in the medical field as a 
biological-containing substance due to its hemocompatibility and biocompatibility18.   
 Polyurethanes are molecular structures that are composed of a hard and soft 
segment that can be selected based on the desired mechanical properties.  Polymerization 
of urethanes is typically done with a catalyst via a condensation reaction.  The structure 
of polyurethane can either consist of benzene rings (aromatic) or hydrocarbon backbones 
(aliphatic diisocyanates)18,19.  The aromatic structure tends to be more chemically stable 
and have more chain strength.  The aliphatic structure is less chemically stable and thus is 
able to be biodegradable18.  Degradation of the aliphatic urethane is carried out though 
hydrolysis, yielding the byproducts of lactic acid and other non-acidic molecules19.  A 
basic molecular structure for polyurethane can be found in Figure 3. 
 
 






1.3.5 Other Coatings 
 There are many other biomaterials that have been used for biomedical 
applications, both degradable and non-degradable. Other biomaterials such as bioglass, 
polycaprolactone, polyester, polymethylmethacrylate (PMMA), and polyglycolic acid 
(PGA) have been used for coatings and drug delivery16,19-21.  Polymers have been 
investigated for applications ranging from PMMA arthrodesis fixation which is non-
degradable to PGA sutures which are degradable.  Polymers vary considerably in their 
mechanical properties, in that they can accommodate both high compressive forces, 
making them appropriate options for load-bearing applications4,13,15, as well as high 
tensile forces, making them useful for soft tissue sutures4,15.  This versatility makes them 
attractive as candidates for most applications associated with orthopaedics including 
antibiotic eluting devices and coatings, where tailorable implants are desirable.   
 In the past, the uses of polymers in antibiotic release or infection prevention have 
been focused on either the addition of antibiotics to PMMA bone cement that can be 
added to joint replacements after revisions due to infection, spacers, or PMMA beads that 
are added to segmented fractures of long bones22.  One disadvantage of PMMA beads for 
use in trauma applications is the requirement of an additional surgery to remove the non-
degradable beads22-23.    
1.3.6 Tobramycin 
 Tobramycin is an aminoglycoside commonly used by orthopaedic surgeons for 
both the treatment of bone infections23 and for infection prophylaxis in open tibial 
fractures24.  The main mechanism of action of tobramycin is inhibition of bacterial 
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protein synthesis24.  Tobramycin is active against some Gram-positive bacteria, including 
Staphylococcus aureus and Staphylococcus epidermidis, and Gram-negative bacteria.   
 Tobramycin was discovered in the 1970’s to be effective in treating Pseudomonas 
aeruginosa and then was adopted as a treatment for cystic fibrosis in the 1990’s24.  
Presently it is used to treat selected severe Gram-positive and most Gram-negative 
infections that are resistant to other more commonly used antibiotics.  One significant 
adverse effect associated with using tobramycin is the potential effect on the liver.  Other 
complications associated with the use of tobramycin are neurotoxicity, ototoxicity, and 
nephrotoxicity23-24.  Adverse side effects typically occur when doses are above the 
therapeutic range.  The mechanism of action of intravenous and intramuscular injections 
necessitates the repeated treatment with antibiotics and checking for toxic serum levels23-
24.  The complications associated with systemic deliver of antibiotics and ability for high 
localized concentrations of antibiotics could be obtained by localized delivery with a 
coating23-24.   
1.3.7 Summary 
 The occurrence of infection associated with extremity trauma treatments is an 
ongoing health problem that can be mitigated, but enhanced treatment methods must be 
pursued.  The scope of the benefit of preventing infection goes beyond the well-being of 
the patient and effects many other aspects of healthcare.  For example, the cost of a 
surgery to repair a fractured hip with a trauma product ranges from approximately 
$14,000 to $24,000 dollars, according to Edwards et al25.  Further, the authors cite an 
increase in cost of approximately 100% when the patient becomes infected post-
surgery25.  In addition to the increased cost associated with infection, the prolonged 
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hospital stay could cause overcrowding, thus reducing staff available to care for new 
patients.  These effects are further compounded when the possibility of revision surgery 
for some patients is considered.   
In recent research, there has been a large emphasis on biocompatible and 
biodegradable polymers for medical use.  The use of a completely biodegradable implant 
for load-bearing fracture fixation has had some setbacks due to issues surrounding their 
mechanical properties and the reaction of the surrounding tissue to the degradation 
products16-17.  However, the use of a biocompatible and biodegradable polymer that can 
be tailored for certain applications, such as local delivery of drugs and or cells, have 
shown much promise.  Potential applications for this technology can be found anywhere 
from stents and heart valves to bone void fillers and implant coatings4.  The proposed 
research will show the efficacy of three different polymer coatings added to bone screws, 
furthermore these preliminary results will also provide information that could be 
generalized to additional applications where the polymer is incorporated into various 
orthopaedic devices.    
One major drawback of the most common local antibiotic carriers is that they are 
not biodegradable.  This drawback can be represented by antibiotic-impregnated PMMA 
beads.  PMMA beads are widely used in severe comminuted fractures with great success; 
however, PMMA is non-degradable and prevents surrounding bone from remodeling 
completely22-23.  While the beads are effective at reducing or potentially eliminating 
infection, the requirement of removal via a second invasive surgery makes them a less 
than ideal final solution to the problem of orthopaedic infection22-23.  The opportunity for 
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a novel biodegradable carrier to transform this clinical therapy is may be possible with 
utilization of the biomaterials evaluated in this research project.   
The biodegradable polymers that will be tested are chitosan, PLA, and degradable 
polyurethane that have been impregnated with tobramycin.  The coated screws will be 
subjected to mechanical tests to assess the adhesive strength of the coatings.   
Additionally, coated screws will undergo biological testing to assess their efficacy.  The 
biological tests will include the effect of screw coatings on growth of bacteria as 
indicated by a zone of inhibition and by the ability of the eluates of the coated screws to 
inhibit growth of bacteria.  These evaluations will provide partial validation of the 




Chapter 2 JOURNAL ARTICLE SUBMISSION 
Efficacy of Three Biodegradable Polymer 
Coatings Loaded with Tobramycin for Bone 
Screws 
 
Zane Hartsell1,2 BS, Joel Bumgardner PhD2 Harry Courtney PhD3, Mark Gosney 
MS1, Warren Haggard PhD2 
1 Smith & Nephew Orthpaedics, Inc 2 University of Memphis  
3 University of Tennessee Health Science Center 
 
 
Objective:  Infection is at an elevated risk in grade three-type long bone fractures.  The 
current method for prophylaxis in a compromised fracture is the administration of 
antibiotics intramuscularly or intravenously.  Both of these administration routes yield 
less than effective antibiotic dosage at the fracture site and in the surrounding tissue.  
Ineffective antibiotic dosage also results from the poor vascular support at the fracture 
site.  With controlled release of antibiotics by a coating on the orthopaedic fracture 
fixation device, an effective antibiotic dosage could be achieved and maintained locally, 
near the contaminated bone fracture.   
Methods:  Sterilized screws (n=15) were coated with chitosan, poly l-lactic acid (PLLA), 
or degradable polyurethane that has been impregnated with 5 wt% tobramycin.  Screws 
(n=5 for each coating type) were then assayed for tobramycin elution profiles, for effect 
of eluates on staphylococcal growth, for zones of inhibition of bacterial growth on agar 
plates, and for effect of screw insertion on coatings   
Results:  Each of the three coating types produced a zone of inhibition of bacterial 
growth of approximately 26 mm in diameter.  The elution study showed that the chitosan 
coating had the largest burst release (1 hour time point) while the PLLA showed a release 
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over 48 hours and the polyurethane produced a consistent elution (79ug/day) over the 168 
hour study.  The polyurethane coating maintained 98.2% adherence after insertion which 
was the highest. Elute from the chitosan coating (1 hour time point) was the only one that 
was able to reduce the S. aureus colony in solution. 




Infection in some extremity trauma is an ongoing clinical problem that requires 
mitigation with current practices to help reduce its rate and the associated health care 
expenses.  The scope of the benefit of preventing infection goes beyond the well-being of 
the patient and effects many other aspects of healthcare.  For example, the cost of a 
surgery to repair a fractured hip via internal plating or intramedullary nailing is between 
$14,000 and $24,000 dollars, according to Edwards et al1.  In contrast, it has been 
reported that the average cost of the first revision due to infection is on the order of 
$100,0002,3.  In addition to the increased cost associated with infection there are also 
concerns with prolonged hospital stay and increased risks of nosocomial infection.  These 
effects are further compounded with the immunocompromised patients of revision 
surgery3.   
Over the last 10 years, a large investment has been made into the research of 
biocompatible and biodegradable polymers for medical use especially in local drug 
delivery and tissue engineering4,5.  The use of a completely biodegradable implant for 
load-bearing fracture fixation with or without antibiotics has had some setbacks due to 
issues surrounding their mechanical properties and the reaction of the surrounding tissue 
to the degradation products6.  The use of a biocompatible and biodegradable polymers 
coupled with metallic components has showed much promise.  Potential applications for 
this technology can be found anywhere from stents and heart valves to implant coatings7.  
This polymer investigation evaluates the efficacy of three different biomaterial polymer 
coatings on bone screws for fracture fixation for local delivery of antibiotics in extremity 
trauma.   
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A major drawback of the most common local antibiotic carriers is their lack of 
biodegradation.  This absence of biodegradation can found in antibiotic impregnated 
PMMA beads and spacers8,9.  The use of PMMA beads is widely used in severe 
comminuted fractures and with great success; however, PMMA is non-degradable and 
prevents the surrounding bone from remodeling completely10.  While the beads are 
effective at reducing or potentially eliminating infection, the requirement for removal 
through a second procedure makes them a less than ideal final solution to the problem of 
infection8-10.  The opportunity for a novel biodegradable carrier to transform clinical 
therapy is possible with utilization of the biomaterial polymers evaluated in this research 
project.   
The purpose of this study was to evaluate three different degradable polymers for 
their potential for use in a contaminated fracture.  The polymers that were tested were 
chitosan, poly l-lactic acid (PLLA), and degradable polyurethane that were impregnated 
with tobramycin.  Bone screws with these coatings were subjected to mechanical tests to 
assess the adhesion strength of the coating as well as the effect of fatigue on the coating 
strength.   Additionally, coated screws underwent biological testing to assess their 
efficacy.  The biological tests included zone of inhibition, activity testing against 
Staphylococcus aureus and elution testing.  The results of in-vitro testing highlight the 
relative performance of the different coatings.  Effectiveness will be defined as retention 
of 80% of coating during insertion, active eluted antibiotics, and antibiotic elution profile 





Methods and Materials 
Sample Preparation 
Samples for all portions of this study were prepared in the same manner.  Prior to 
coating, the 4.5mm cortical bone screws (Smith & Nephew, Inc) were cleaned and 
ultrasonicated in methanol and autoclaved using a pre vacuum cycle at 54.4°C for 4 
minutes (SV-116, Steris Co., Mentor, OH).  All samples received their respective coating 
impregnated with 5 wt% Tobramycin (Fisher Scientific, Pittsburg, PA) with the 
following methods. 
The screws for this study were all coated by a dip coating process.  To produce 
the chitosan coating, 2.0g of 80% DDA chitosan (Vanson Halosource, Bothel, Wa) was 
combined with 30mL of deionized water in a 50mL vial.  1.5mL of Lactic and 0.5mL of 
acetic acid were then added to the vial and mixed until the solution was homogeneous.  
Tobramycin was then added at 5wt% and then the solution was placed on a vortex mixer 
(Mini Vortexer, VWR, Radnor, PA) until well mixed. The screws were then manually 
dipped once into the solution for approximately one second.   
The PLLA coating was produced by mixing 2.65g of PLLA (PURASORB 38 
Purac, Gorinchem, Netherlands) and 50mL of chloroform.  The solution was placed in an 
oil bath at 50°C with a stir bar to facilitate dissolving the PLLA.  Tobramycin was then 
added to the solution at 5 wt% and mixing continued till homogenous.  The screws were 
then manually dipped once into the solution for approximately one second. 
A polyurethane coating was produced by mixing 10g of pre-polymer A 
(isocynate) and pre-polymer B (aliphatic) at a 70/30 ratio (PolyNovo, Port Melbourne, 
Australia). The pre-polymer mixture then added to a premixed solution (5mg of 
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dibutyltin dilaurate (Sn catalyst), 6.67g of chloroform (CHCl3), and 5 wt% tobramycin) 
and was mixed until homogeneous.  The screws were then manually dipped once into the 
solution for approximately one second.    
All screws were dipped ½ of the way up the shaft of the screw (Figure 1a).  To 
facilitate drying and to help ensure even coatings, all screws were fixed on a custom 
rotating fixture (30 RPM) such that they were perpendicular to the ground (Figure 1b).   
 
 
Figure 1. Coated screws (A), Custom drying fixture (B) 
 
Zone of Inhibition Testing 
 To test the ability of the coated screws to inhibit growth of S. aureus, a zone of 
inhibition test was performed.  S. aureus Cowan I strain was grown overnight at 37°C in 
Tryptic soy broth (TSB) and a 100 µl aliquot of 1:10 dilution of the overnight growth of 
S. aureus was plated on TSB agar plates.  Bone screws coated with each coating material 
(n=3) and loaded with 5% tobramycin were then added to the agar plates and pressed 
down to ensure maximum contact with the substrate.  Plates were then incubated for 24 




zone surrounding the screw.  The diameters of the zones of inhibition were measured 
perpendicular to the shaft of the screw.   
Elution Testing 
 The capability of the coatings to have a sustainable release and desirable 
antibiotic elution profile was assessed over a 7 day period.  Screws coated with each 
coating type (n=5) were weighed prior to commencement of testing.  2mL of phosphate 
buffered solution (PBS) was added to the 5mL vials containing the screws and they were 
placed in an oscillating incubator set at 37°C oscillating at 50 rpm (Barnstead Max Q 
400, Thermo Scientific, Waltham, MA).  Due to the small volume of the test media the 
solubility of tobramycin was checked to be 538mg/mL, therefore the ability to suspend 
all the eluted tobramycin was not problematic.  The PBS solution was removed and 
stored for analysis and replaced with fresh PBS at the following time points:  1, 2, 4, 8, 
12, 24, 48, 72, 96, and 168 hours.  Upon collection of the PBS solution, samples were 
frozen (-20°C) until analysis.  Analysis of the solution was done by a TDxFLx instrument 
(Abbott Laboratories, Abbott Park, IL).  Calibration was done prior to testing with a 0.5, 
4, and 8 µL/mL concentration calibration kit.  For specimen analysis, 80µL of the 
collected samples was added to the sample tray.  Some samples were retested at higher 
dilutions due to them being out of the calibration range of the instrument.  
Testing for Antimicrobial Activity 
 Antimicrobial activity testing was performed to evaluate the efficacy of the 
tobramycin in the eluates to inhibit bacterial growth.  S. aureus Cowan I strain was grown 
overnight at 37°C in TSB and diluted 1:5 with TSB.   Tubes were prepared containing the 
following: 1.75 ml of TSB, 200 µl from each eluate, and an inoculum of 50 µl of the 1:5 
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dilutions of S. aureus.    Positive controls consisted of tubes in which 200 µl of the eluate 
was replaced with 200 µl of PBS.  Negative controls consisted of tubes in which 50 µl of 
TSB was used instead of 50 µl of S. aureus. All samples of eluate were diluted 1:10 for 
antimicrobial assays according to previous testing protocols12.  The tubes were incubated 
at 37°C for 18 hours and then the absorbance at a 530nm (A530) was measured on a 
spectrophotometer (Spectronic 20 Genesys: model 4001, Thermo Scientific).  
Insertion Testing 
 Insertion testing was performed to evaluate the adherence of the coating as well as 
to determine if the addition of the coating altered the needed torque for insertion.  
Prepared 1 inch thick blocks of 20 pcf foam (General Plastic, Last-a-foam 3720) received 
a 3.5mm predrill per the manufacturer’s surgical technique11.  The blocks were then 
attached to a custom screw testing machine (Figure 2).  The coated screws (n=5) of each 
material were then inserted at a rate of 5RPM with a 22.24N force in line with the long 
axis of the screw to ensure engagement in the foam.  The screws were inserted for 10 
revolutions.  LabView (v8.0, National Instruments, Austin, TX) was used to record the 
maximum torque produced during insertion, and the screws were weighed after testing to 




Figure 2. Screw insertion test setup 
 
Statistical Analysis 
The results of the individual experiments were evaluated using statistical 
comparisons done with ANOVA single-factor using Tukey method with significance 
declared at 95% confidence (Minitab 16, State College, PA). 
Results 
Zone of Inhibition Testing 
The zone of inhibition test was used to determine if the antibiotic remained active 
after the use the solvents used in coating process or any other aspect of the coating 
procedures.  It was shown there was an initial kill zone for all coating types and they 
were of similar size. Each of the coating types produced a zone of inhibition of bacterial 
growth of approximately 26 mm in diameter (range 25-29 mm), and there was no 
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statistically significant difference between the coatings.  This result was consistent with 
Greene et al.12 who coated stainless steel with gentamicin impregnated chitosan and saw 
a similar zone of inhibition. Representative images from the uncoated and coated screws 
can be seen in figure 3.   
 
       
Figure 3: Representative zone of inhibition results: uncoated(left) and PLA coated(right) 
 
Testing of the eluates for antimicrobial activity showed that there was only 
inhibition of bacterial growth at the 1 hour time point for the chitosan samples.  This was 
due to the burst release of tobramycin.  The other specimen’s aliquots were not able to 
inhibit the growth of S. aureus.  Since the solution was exchanged at each time point, the 
additive effect of the previous time point’s elution could not be assessed. 
Profile of Antibiotic Elution 
 The elution testing showed that the elution profiles of the three coatings were 
dissimilar in amount released and time of release (Figure 4).  The chitosan samples 
showed a large burst release in the first hour of the elution testing.  This burst release was 
likely due to the disassociation of the coating from the screw in the testing environment 
and therefore the subsequent time points did not yield any additional tobramycin elution 
20 
 
for the chitosan samples.  The PLLA screws also showed a burst release, albeit of a lower 
magnitude, followed by a steadily tapering elution over the next 7 days.  The 
polyurethane coated screws showed the smallest burst release with the most consistent 
release over time.  The most effective release profile for bacterial inhibition to prevent 
infection is not completely known.  Many researchers have suggested a burst release 
followed by a continued release above the minimum inhibitory concentration of the 
contaminating bacteria13.  
 
Figure 4. Elution testing results of Chitosan(A), PLLA(B), and Polyurethane(C).  Dashed 






















































 Insertion testing was used to evaluate the potential increase in screw insertion 
force with the different coatings as well as to quantify the amount of coating that was lost 
due to insertion into a foam bone surrogate.  The insertion torque generated for the coated 
screws was 1.70±0.22, 2.02±0.24, and 2.91±0.54 in-lbf, for the chitosan, PLLA and 
polyurethane, respectively (Figure 5).  The insertion torque generated by all three 
coatings showed a statistically significant increase (p>0.05) from the uncoated screw.  
Additionally, the insertion torque of each coated screw was significantly different 
(p<0.05) than the others, with the insertion torque of the polyurethane group being the 
highest.   
 
 































The results of the coating lost during insertion weight measurement showed that 
the chitosan-coated screws exhibited the highest amount of coating lost, followed by the 
PLLA and the polyurethane, respectively (Figure 6).  The percentage of coating lost was 
21.18±18.03%, 3.3±2.53%, and 1.78±0.89% for the chitosan, PLLA and polyurethane, 
respectively.  These results indicate that under insertion, the polyurethane coating 
produces the most resistance to delamination from the substrate.   
 
 
Figure 6. Results of coating lost during insertion testing 
Discussion 
In a review article by Hofmann et al. the use of biodegradable polymer coatings to 
elute antibiotics has been described by many researchers in the past has shown great 



























the mechanical, biological, as well as efficacy of the coatings to prevent bacteria 
proliferation.  It was the aim of this study to directly compare three such coatings under 
identical conditions to be able to quantify their advantages and disadvantages.   
Interestingly, these results showed delamination of chitosan and release of the 
majority of the antibiotic in the first hour of the elution study.  The delamination is not 
consistent with Greene et al.12 that showed coating attachment over a 96 hour elution 
study.   One potential reason for this difference is the coating method used by Greene 
involved a silane treatment which has been shown to increase surface adherence.  
However, the elution of the majority of the antibiotics was consistent with Greene et al.12 
and Aimin et al.15 which both showed a nearly 10 fold decrease in elution amount from 
the first to the second time point of their respective elution studies using antibiotic loaded 
chitosan.  The PLA curve was also consistent with literature.  Mader et al.16 showed in a 
longer elution study of tobramycin from PLA a peak release rate at day 2 and then a drop 
off for the remainder of the time points out to 42 days.   
The use of other polymers such as polycaprolactone and polylactic acid\glycolic 
acid in other studies have shown efficacy in situations where bacteria was present16,17.  
The benefit in this study, as well as studies by Mader et al.16  and Chang et al.18, is that 
they show the elution and beginning of degradation of biodegradable polymers.  This 
research as well as other studies12-15 show the potential for and need for a biodegradable 
polymer that can locally release antibiotics and not have to be removed prior to 
consolidation of the bone. 
 Biodegradable polymer coating of orthopaedic implants is one of the potential 
methods of infection prevention in open fractures.  The ability to add antibiotics to 
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biodegradable polymers and to manipulate their degradation profiles offers an attractive 
option for infection prevention and control.  The localization and controlled release from 
coated fracture fixation devices of the antibiotics could enhance the control of infections 
in complex or compromised trauma injuries. 
 This polymer study illustrates the possible benefits and limitations for three 
polymeric coatings.  While all three coatings inhibited the growth of S. aureus on agar 
plates, the chitosan coating was the only coating eluted a tobramycin concentration that 
reduced the S. aureus colony in solution, and only at the earliest time point.  The 
polyurethane coating provided the most resistance to delamination during implantation 
and potentially produces an attractive elution profile.  Future studies with higher 
antibiotic loading levels will be pursued to determine if the coatings can provide infection 
prevention over a more extended period of time.   
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Chapter 3 CONCLUSIONS 
 The research conducted for this thesis was to assess the potential for three 
different degradable polymeric coatings to be applied to bone fracture fixation devices in 
the hope of preventing infection and or colonization of bacteria in compromised or open 
fractures.  To evaluate the potential efficacy, three degradable antibiotic coatings were 
applied to orthopaedic bone screws and testing under simulated physiological conditions.  
The coatings used were PLLA, chitosan, and polyurethane.  This included insertion 
testing to evaluate coating adhesion strength, zone of inhibition testing to evaluate if the 
antibiotic is still biologically active, elution testing to determine the release profiles, and 
activity testing to evaluate eluted antibiotic efficacy over time.    
 The mechanical testing performed showed that the polyurethane produced the 
coating most adhered to the screw surface.  The adherence ranking was followed by the 
PLLA and chitosan coatings.  The zone of inhibition testing showed no difference 
between the coatings with all of the coatings yielding a similar size and shaped clear 
zones around the coated implant after 24 hours against S. aureus.  This zone of inhibition 
evaluation demonstrated that the coating techniques and solvents maintain some 
antibiotic activity for the tobramycin. 
 When evaluating the release of the antibiotics from the degradable coatings, each 
of the evaluated coatings did produce a unique elution curve.  The chitosan coating 
produced a burst release in the first hour with almost complete elution of all of the 
antibiotics in the coating.  The PLA and polyurethane coatings both had extended elution 
periods that spanned the seven day test.  The profile of the PLA was characterized by an 
initial burst release over the first 24 hours and then a gradual decrease through the 
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seventh day.  The polyurethane coating profile showed a nearly linear elution curve after 
the burst release in the first hour.  Activity testing was completed on all aliquots collected 
from the elution study and the only sample that yielded a concentration above the 
minimum inhibitory concentration was the first hour’s release of the chitosan sample due 
to the burst release.  Therefore, the coatings selected for this research each showed 





Chapter 4  FUTURE WORK 
 The presented work will need to be followed up with much iteration for 
formulations as well as experiments to test the preclinical efficacy prior to clinical 
studies.  Initially there will need to be a more extensive quantification of the coating 
applied to the implant.  Coating thicknesses were optimized on flat disks prior to 
incorporation of the bone screw.  Further optimization will need to be done on screws to 
maintain consistent thicknesses between coating types.  Additionally, the effect of coated 
screws without the incorporation of antibiotics needs to be evaluated to measure the 
ability of the virgin coating to inhibit bacterial growth or any potential solvent residue 
leaching.  This will allow a more accurate assessment of the benefit of the incorporated 
antibiotics. 
The current antibiotic loading level was only effective in inhibiting the growth of 
Gram-positive bacteria but not reduction in bacterial presence over time.  If the thin 
coating of an implant it is to be effective in preventing biofilm and reduction of bacterial 
presence in tissue future iterations will need to have a higher concentration of antibiotics.  
Additionally, the use in trauma applications will necessitate the use of, at a minimum, six 
screws for fixation.  The additional screws would allow for the additive effect when 
evaluating if the MIC level can be reached.  The mechanism and potential for this 
phenomenon will need to be assessed.   
 After creating an effective elution profile, another opportunity for future work for 
this project will be the incorporation of an animal model.  A small animal model would 
be used to test the efficacy of the coating in preventing infection.  A rabbit model would 
be ideal due to its wide spread use in orthopaedic implant studies.  A 1 cm segment of 
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bone would be removed from the rabbit’s femur and then the bone would be fixed with a 
small plate and fixed with coated screws.  Fixation would likely be done with a plate 
intended for the hand or fibula.  Prior to closure the fracture site would be inoculated via 
an injection of S. aureus inoculum.  Additionally, the efficacy of the coating in the 
elimination of a biofilm could be tested in an animal model.  This animal model will lead 
to a better understanding of the additive effect of the antibiotics and the clearance rate of 
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This appendix will persent additional figures and data that was not put into the main body 
of the thesis. 
 
  
The above image was captured to show the addition of chitosan coating to the bone 











The elution study was completed in an oscillating incubater (seen above) with the screws 
sitting vertically in the sealed vials.  The PBS for media excange was also kept in the 
same incubater to ensure that there was not a period of time  where the media was 




The above image showes the oil bath and associated glass ware used for desolving , 
mixing, and heating the PLLA prior to coating the screws.  Water was continuoulsy 





After coating photographs were taken of different samples from each coating group.  The 
image above represents the following: polyurethane (left), PLLA (center), and chitosan 





After elution testing analysis was done to compare the theoretical amount of tobramycin 
loaded onto each screw based on coating thicknesses.  All values were normalized based 





































The above image shows the complete zone of inhibition results from each of the coating 
groups.  The third sample of the chitosan group has different shape due to the screws 
being dropped in the dish prior to seating it in its final position.  This however did not 








uncoated -1 0 
uncoated -2 0 




















The tables above represent the raw data associated with the measurements taken after the 







Coating thicknesses as measured by a JOEL SEM of the degradable polyurethane of 
A)20 wt%, B) 27 wt%, C) 60 wt%, and D) 70 wt% polymer in chloroform solvent.  





Statistical comparisons were made using ANOVA single-factor; in order to make 
multiple comparisons, the Tukey method was used post-hoc  (α=0.05). 
 
 
One-way ANOVA: insertion torque versus coating  
 
Source   DF     SS     MS      F      P 
coating   3  4.958  1.653  14.47  0.000 
Error    15  1.713  0.114 
Total    18  6.671 
 
S = 0.3380   R-Sq = 74.32%   R-Sq(adj) = 69.18% 
 
 
                             Individual 95% CIs For Mean Based on 
                             Pooled StDev 
Level     N    Mean   StDev  ---+---------+---------+---------+------ 
Chitosan  6  1.6993  0.2244        (----*----) 
PLLA      6  2.0255  0.2380              (----*----) 
PU        5  2.9056  0.5423                            (----*-----) 
uncoated  2  1.5015  0.0460  (-------*--------) 
                             ---+---------+---------+---------+------ 
                              1.20      1.80      2.40      3.00 
 
Pooled StDev = 0.3380 
 
 
Tukey 95% Simultaneous Confidence Intervals 
All Pairwise Comparisons among Levels of coating 
 
Individual confidence level = 98.87% 
 
 
coating = Chitosan subtracted from: 
 
coating     Lower   Center   Upper  --------+---------+---------+---------+- 
PLLA      -0.2368   0.3262  0.8891                  (----*---) 
PU         0.6158   1.2063  1.7967                         (----*----) 
uncoated  -0.9940  -0.1978  0.5983            (-----*------) 
                                    --------+---------+---------+---------+- 
                                         -1.2       0.0       1.2       2.4 
 
 
coating = PLLA subtracted from: 
 
coating     Lower   Center   Upper  --------+---------+---------+---------+- 
PU         0.2897   0.8801  1.4705                      (----*----) 
uncoated  -1.3201  -0.5240  0.2721         (------*-----) 
                                    --------+---------+---------+---------+- 
                                         -1.2       0.0       1.2       2.4 
 
 
coating = PU subtracted from: 
 
coating     Lower   Center    Upper  --------+---------+---------+---------+- 
uncoated  -2.2199  -1.4041  -0.5883  (-----*------) 
                                     --------+---------+---------+---------+- 





One-way ANOVA: % coating lost versus coating  
 
Source   DF    SS   MS     F      P 
coating   2  1345  673  5.67  0.016 
Error    14  1660  119 
Total    16  3005 
 
S = 10.89   R-Sq = 44.76%   R-Sq(adj) = 36.87% 
 
 
                           Individual 95% CIs For Mean Based on 
                           Pooled StDev 
Level     N   Mean  StDev  ---------+---------+---------+---------+ 
Chitosan  6  21.18  18.03                       (--------*---------) 
PLLA      6   3.30   2.53     (--------*---------) 
PU        5   1.78   0.89  (----------*---------) 
                           ---------+---------+---------+---------+ 
                                    0        10        20        30 
 
Pooled StDev = 10.89 
 
 
Tukey 95% Simultaneous Confidence Intervals 
All Pairwise Comparisons among Levels of coating 
 
Individual confidence level = 97.97% 
 
 
coating = Chitosan subtracted from: 
 
coating   Lower  Center  Upper  ----+---------+---------+---------+----- 
PLLA     -34.33  -17.88  -1.43   (----------*----------) 
PU       -36.65  -19.40  -2.15  (----------*-----------) 
                                ----+---------+---------+---------+----- 
                                  -30       -15         0        15 
 
 
coating = PLLA subtracted from: 
 
coating   Lower  Center  Upper  ----+---------+---------+---------+----- 
PU       -18.77   -1.52  15.73             (-----------*----------) 
                                ----+---------+---------+---------+----- 







One-way ANOVA: zone of inhibition versus coating  
 
Source   DF       SS      MS       F      P 
coating   3  1510.92  503.64  402.91  0.000 
Error     8    10.00    1.25 
Total    11  1520.92 
 
S = 1.118   R-Sq = 99.34%   R-Sq(adj) = 99.10% 
 
 
                            Individual 95% CIs For Mean Based on 
                            Pooled StDev 
Level     N    Mean  StDev  --+---------+---------+---------+------- 
CH        3  26.667  2.082                                   (-*-) 
PLLA      3  25.333  0.577                                  (-*-) 
PU        3  25.667  0.577                                  (-*-) 
uncoated  3   0.000  0.000  (-*-) 
                            --+---------+---------+---------+------- 
                            0.0       8.0      16.0      24.0 
 
Pooled StDev = 1.118 
 
 
Tukey 95% Simultaneous Confidence Intervals 
All Pairwise Comparisons among Levels of coating 
 
Individual confidence level = 98.74% 
 
 
coating = CH subtracted from: 
 
coating     Lower   Center    Upper    +---------+---------+---------+--------- 
PLLA       -4.257   -1.333    1.591                     (-*-) 
PU         -3.924   -1.000    1.924                     (-*-) 
uncoated  -29.591  -26.667  -23.743    (-*-) 
                                       +---------+---------+---------+--------- 
                                     -30       -15         0        15 
 
 
coating = PLLA subtracted from: 
 
coating     Lower   Center    Upper    +---------+---------+---------+--------- 
PU         -2.591    0.333    3.257                      (-*-) 
uncoated  -28.257  -25.333  -22.409     (-*-) 
                                       +---------+---------+---------+--------- 
                                     -30       -15         0        15 
 
 
coating = PU subtracted from: 
 
coating     Lower   Center    Upper    +---------+---------+---------+--------- 
uncoated  -28.591  -25.667  -22.743     (-*-) 
                                       +---------+---------+---------+--------- 




























































Test for Equal Variances for insertion torque
 
 
